timothy sykes logo

Stock News

Crispr Therapeutics Shares Surge as Analysts Increase Price Targets

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 2/15/2026, 11:22 am ET 2/15/2026, 11:22 am ET | 5 min 5 min read
Crispr Therapeutics Shares Surge as Analysts Increase Price Targets Thumbnail

CRISPR Therapeutics AG stocks have been trading up by 8.05 percent amid promising genetic therapy advancements.

Healthcare industry expert:

Analyst sentiment – positive

Crispr Therapeutics (CRSP) presents a challenging market position marked by substantial deficits in profitability metrics and strained income statements, underscoring its speculative status within the biotechnology sector. The company’s EBIT margin of -17,094.9 and a negative EBITDA margin further highlight severe operational inefficiencies. Despite an alarming profit margin of -16,569.77%, CRSP displays a robust gross margin of 3,415.6%, suggesting potential benefits from economies of scale or premium pricing capabilities. The company’s financial strength is evident with a low debt-to-equity ratio of 0.11 and high liquidity ratios, including a current and quick ratio of 13.3, positioning it favorably amidst uncertain market conditions. Significant free cash flow deficit of -$93.07 million, alongside negative operating and investing cash flows, underscores unsustainable cash burn unless revenue scales significantly or new capital funding is secured.

From a technical analysis perspective, CRSP’s recent price actions indicate a short-term positive trend with a sharp upward movement, closing at $53.07 from the week’s low of $48.25. The price spiked following a sustained period of sideways movement and consolidations, explicitly visible in large volume trades particularly on the closing day. The support level sits near $48.25, coinciding with recent low. Key resistance level at $54.10, the weekly high, is pivotal for confirming a continued upward breakout. Given these technical insights, traders could employ a buy strategy prepared to add positions above the $54.10 resistance with a stop-loss below the $48.25 support level to minimize potential downside risks.

The recent spike in Crispr Therapeutics’ stock comes amid a wave of positive analyst sentiment and strategic investments, notably by prominent stakeholders like Cathie Wood’s ARK Investment. Analysts across various investment firms have raised price targets following Casgevy’s promising market projections as highlighted by partnerships with Vertex Pharmaceuticals. This places CRSP in favorable alignment with broader sector expectations. Price targets range between $74 and $82, reflecting strong upward momentum. Nevertheless, caution is warranted given the inherent volatility in biotechnology and recent profit-taking behaviors. Overall, Crispr Therapeutics stands in a growth phase dominated by a robust R&D pipeline, providing a promising yet risky proposition when matched against sector benchmarks. The outlook is bolstered by upcoming clinical updates and potentially transformative treatments under development.

Candlestick Chart

Weekly Update Feb 09 – Feb 13, 2026: On Sunday, February 15, 2026 CRISPR Therapeutics AG stock [NASDAQ: CRSP] is trending up by 8.05%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Crisper Therapeutics presents a complex financial picture, with a mix of promising revenue forecasts but also significant challenges. Its revenue stands at a modest $3.51M; when compared to its valuation, the price-to-sales ratio is astoundingly high at 132.9. This underlines an overvaluation risk if sales growth doesn’t accelerate. The company has a solid current ratio of 13.3, showcasing liquidity strength, an essential buffer for ongoing biotech R&D.

The financials reflect substantial losses with a net income from continuing operations at -$130.61M, marking a high-risk investment profile despite the burgeoning gene-editing market potential. Analyst optimism, reflected in upward revisions of price targets, hinges on the performance of Casgevy, whose sales projections are impressively high, augmented by strategic collaborations such as with Vertex Pharmaceuticals.

More Breaking News

In the short-term, the stock displayed volatility. For instance, it saw a high of $54.10 before closing at $53.07, exhibiting an upward momentum. This momentum is reinforced by buy ratings from reputable analysis firms, alongside important strategic investments—like Cathie Wood’s ARK Invest—fueling interest and potential upward price cycles in subsequent trading sessions.

Conclusion

In summary, Crispr Therapeutics stands as a high-stakes, high-reward profile in the biotechnology sector. Analyst optimism and strategic investments hint at a promising trajectory, primarily fueled by the impressive sales potential of Casgevy and transformative research partnerships. While the stock currently navigates a delicate balance between overvaluation concerns and a promising scientific breakthrough horizon, traders appear keen to maintain a long position based on its strategic R&D direction and anticipated market growth dynamics in genetic medicine. However, as millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.” This sentiment serves as a reminder for traders eyeing Crispr Therapeutics to carefully weigh their decisions amidst the volatile and competitive landscape of genetic medicine.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”